Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin BID vs QD in T2DM on Metformin
NCT01217892Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2010
- Primary completion
- Aug 2011
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of dapagliflozin in type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Started Nov 2010; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01217892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01217892.